{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:14:39Z","timestamp":1762460079024,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1141921","1082022","1080001","1028634","1028641","1126399"],"award-info":[{"award-number":["1141921","1082022","1080001","1028634","1028641","1126399"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian Centre for Immunotherapy and Vaccine Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Artemisinin-based combination therapy (ACT) has been a mainstay for malaria prevention and treatment. However, emergence of drug resistance has incentivised development of new drugs. Defining the kinetics with which circulating parasitized red blood cells (pRBC) are lost after drug treatment, referred to as the \u201cparasite clearance curve\u201d, has been critical for assessing drug efficacy; yet underlying mechanisms remain partly unresolved. The clearance curve may be shaped both by the rate at which drugs kill parasites, and the rate at which drug-affected parasites are removed from circulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this context, two anti-malarials, SJ733, and an ACT partner drug, pyronaridine were compared against sodium artesunate in mice infected with <jats:italic>Plasmodium berghei<\/jats:italic> (strain ANKA). To measure each compound\u2019s capacity for pRBC removal in vivo, flow cytometric monitoring of a single cohort of fluorescently-labelled pRBC was employed, and combined with ex vivo parasite culture to assess parasite maturation and replication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>These three compounds were found to be similarly efficacious in controlling established infection by reducing overall parasitaemia. While sodium artesunate acted relatively consistently across the life-stages, single-dose SJ733 elicited a biphasic effect, triggering rapid, partly phagocyte-dependent removal of trophozoites and schizonts, followed by arrest of residual ring-stages. In contrast, pyronaridine abrogated maturation of younger parasites, with less pronounced effects on mature parasites, while modestly increasing pRBC removal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anti-malarials SJ733 and pyronaridine, though similarly efficacious in reducing overall parasitaemia in mice, differed markedly in their capacity to arrest replication and remove pRBC from circulation. Thus, similar parasite clearance curves can result for anti-malarials with distinct capacities to inhibit, kill and clear parasites.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04075-z","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T08:06:26Z","timestamp":1644998786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice"],"prefix":"10.1186","volume":"21","author":[{"given":"Arya","family":"SheelaNair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra S.","family":"Romanczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary A.","family":"Aogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit Nemai","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne I. M.","family":"Lansink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Cromer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yandira G.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Kiplin","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraful","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":false,"given":"David S.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"4075_CR1","volume-title":"World Malaria Report 2019","author":"WHO Global Malaria Programme","year":"2019","unstructured":"WHO Global Malaria Programme. World Malaria Report 2019. Geneva: World Health Organization; 2019."},{"key":"4075_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5694\/j.1326-5377.2005.tb06650.x","volume":"182","author":"TM Davis","year":"2005","unstructured":"Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust. 2005;182:181\u20135.","journal-title":"Med J Aust"},{"key":"4075_CR3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1473-3099(19)30394-9","volume":"19","author":"D Menard","year":"2019","unstructured":"Menard D, Fidock DA. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. Lancet Infect Dis. 2019;19:916\u20137.","journal-title":"Lancet Infect Dis"},{"key":"4075_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.pt.2020.02.005","volume":"36","author":"DS Khoury","year":"2020","unstructured":"Khoury DS, Zaloumis SG, Grigg MJ, Haque A, Davenport MP. Interdisciplinary Approaches to Malaria C. Malaria parasite clearance: what are we really measuring? Trends Parasitol. 2020;36:413\u201326.","journal-title":"Trends Parasitol"},{"key":"4075_CR5","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/infdis\/jiaa678","volume":"223","author":"M Rebelo","year":"2021","unstructured":"Rebelo M, Pawliw R, Gower J, Webb L, Mitchell H, Pava Z, et al. Parasite viability as a superior measure of antimalarial drug activity in humans. J Infect Dis. 2021;223:2154\u201363.","journal-title":"J Infect Dis"},{"key":"4075_CR6","doi-asserted-by":"publisher","first-page":"e1007599","DOI":"10.1371\/journal.ppat.1007599","volume":"15","author":"J Akter","year":"2019","unstructured":"Akter J, Khoury DS, Aogo R, Lansink LIM, SheelaNair A, Thomas BS, et al. Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells. PLoS Pathog. 2019;15:e1007599.","journal-title":"PLoS Pathog"},{"key":"4075_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ijpara.2018.05.010","volume":"48","author":"RA Aogo","year":"2018","unstructured":"Aogo RA, Khoury DS, Cromer D, Elliott T, Akter J, Fogg LG, et al. Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice. Int J Parasitol. 2018;48:903\u201313.","journal-title":"Int J Parasitol"},{"key":"4075_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ijpara.2017.05.009","volume":"47","author":"DS Khoury","year":"2017","unstructured":"Khoury DS, Cromer D, Elliott T, Soon MSF, Thomas BS, James KR, et al. Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo. Int J Parasitol. 2017;47:913\u201322.","journal-title":"Int J Parasitol"},{"key":"4075_CR9","doi-asserted-by":"publisher","first-page":"7701","DOI":"10.1073\/pnas.1618939114","volume":"114","author":"DS Khoury","year":"2017","unstructured":"Khoury DS, Cromer D, Akter J, Sebina I, Elliott T, Thomas BS, et al. Host-mediated impairment of parasite maturation during blood-stage Plasmodium infection. Proc Natl Acad Sci USA. 2017;114:7701\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4075_CR10","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ijpara.2011.07.010","volume":"41","author":"SH Apte","year":"2011","unstructured":"Apte SH, Groves PL, Roddick JS, da Hora VP, Doolan DL. High-throughput multi-parameter flow-cytometric analysis from micro-quantities of Plasmodium-infected blood. Int J Parasitol. 2011;41:1285\u201394.","journal-title":"Int J Parasitol"},{"key":"4075_CR11","doi-asserted-by":"publisher","first-page":"E5455","DOI":"10.1073\/pnas.1414221111","volume":"111","author":"MB Jimenez-Diaz","year":"2014","unstructured":"Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci USA. 2014;111:E5455\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4075_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1475-2875-11-270","volume":"11","author":"SL Croft","year":"2012","unstructured":"Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012;11:270.","journal-title":"Malar J"},{"key":"4075_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S1473-3099(19)30611-5","volume":"20","author":"AH Gaur","year":"2020","unstructured":"Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, et al. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a\/b trial. Lancet Infect Dis. 2020;20:964\u201375.","journal-title":"Lancet Infect Dis"},{"key":"4075_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12936-015-0957-z","volume":"14","author":"X Deng","year":"2015","unstructured":"Deng X, Duffy SP, Myrand-Lapierre ME, Matthews K, Santoso AT, Du YL, et al. Reduced deformability of parasitized red blood cells as a biomarker for anti-malarial drug efficacy. Malar J. 2015;14:428.","journal-title":"Malar J"},{"key":"4075_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/infdis\/jiv358","volume":"213","author":"R Zhang","year":"2016","unstructured":"Zhang R, Suwanarusk R, Malleret B, Cooke BM, Nosten F, Lau YL, et al. A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609. J Infect Dis. 2016;213:100\u20134.","journal-title":"J Infect Dis"},{"key":"4075_CR16","doi-asserted-by":"publisher","first-page":"e00394","DOI":"10.1128\/AAC.00394-18","volume":"62","author":"WA Okoth","year":"2018","unstructured":"Okoth WA, Dukes EJ, Sullivan DJ Jr. Superior pyronaridine single-dose pharmacodynamics compared to artesunate, chloroquine, and amodiaquine in a murine malaria luciferase model. Antimicrob Agents Chemother. 2018;62:e00394-e418.","journal-title":"Antimicrob Agents Chemother"},{"key":"4075_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1475-2875-11-45","volume":"11","author":"A Pascual","year":"2012","unstructured":"Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, et al. Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J. 2012;11:45.","journal-title":"Malar J"},{"key":"4075_CR18","doi-asserted-by":"publisher","first-page":"e1003669","DOI":"10.1371\/journal.pmed.1003669","volume":"18","author":"G Tona Lutete","year":"2021","unstructured":"Tona Lutete G, Mombo-Ngoma G, Assi SB, Bigoga JD, Koukouikila-Koussounda F, Ntamabyaliro NY, et al. Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study. PLoS Med. 2021;18:e1003669.","journal-title":"PLoS Med"},{"key":"4075_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","volume":"391","author":"West African Network for Clinical Trials of Antimalarial D","year":"2018","unstructured":"West African Network for Clinical Trials of Antimalarial D. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial. Lancet. 2018;391:1378\u201390.","journal-title":"Lancet"},{"key":"4075_CR20","doi-asserted-by":"publisher","first-page":"14509","DOI":"10.1073\/pnas.0806727105","volume":"105","author":"RJ Lundie","year":"2008","unstructured":"Lundie RJ, de Koning-Ward TF, Davey GM, Nie CQ, Hansen DS, Lau LS, et al. Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci USA. 2008;105:14509\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4075_CR21","doi-asserted-by":"publisher","first-page":"6148","DOI":"10.4049\/jimmunol.1003955","volume":"186","author":"A Haque","year":"2011","unstructured":"Haque A, Best SE, Unosson K, Amante FH, de Labastida F, Anstey NM, et al. Granzyme B expression by CD8+ T cells is required for the development of experimental cerebral malaria. J Immunol. 2011;186:6148\u201356.","journal-title":"J Immunol"},{"key":"4075_CR22","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ijpara.2006.07.009","volume":"36","author":"D Cromer","year":"2006","unstructured":"Cromer D, Evans KJ, Schofield L, Davenport MP. Preferential invasion of reticulocytes during late-stage Plasmodium berghei infection accounts for reduced circulating reticulocyte levels. Int J Parasitol. 2006;36:1389\u201397.","journal-title":"Int J Parasitol"},{"key":"4075_CR23","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1128\/IAI.01210-10","volume":"79","author":"A Haque","year":"2011","unstructured":"Haque A, Best SE, Amante FH, Ammerdorffer A, de Labastida F, Pereira T, et al. High parasite burdens cause liver damage in mice following Plasmodium berghei ANKA infection independently of CD8(+) T cell-mediated immune pathology. Infect Immun. 2011;79:1882\u20138.","journal-title":"Infect Immun"},{"key":"4075_CR24","doi-asserted-by":"publisher","first-page":"e1001221","DOI":"10.1371\/journal.ppat.1001221","volume":"6","author":"A Haque","year":"2010","unstructured":"Haque A, Best SE, Amante FH, Mustafah S, Desbarrieres L, de Labastida F, et al. CD4+ natural regulatory T cells prevent experimental cerebral malaria via CTLA-4 when expanded in vivo. PLoS Pathog. 2010;6:e1001221.","journal-title":"PLoS Pathog"},{"key":"4075_CR25","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1128\/AAC.00119-06","volume":"50","author":"S Auparakkitanon","year":"2006","unstructured":"Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P. Targeting of hematin by the antimalarial pyronaridine. Antimicrob Agents Chemother. 2006;50:2197\u2013200.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04075-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04075-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04075-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T08:08:25Z","timestamp":1644998905000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04075-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4075"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04075-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"type":"electronic","value":"1475-2875"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"7 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures and protocols were approved (A02-633M and A1503-601M) and monitored by the QIMR Berghofer Medical Research Institute Animal Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RKG is named inventor on US Patent 9,416,124, which protects SJ733 intellectual property, and receives compensation from any patent royalties associated with that patent. The authors have no other competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}